Table 2.
Characteristics of the cohort by development of COVID-19 infection.
| Characteristics | COVID-19+ n = 103 |
COVID-19− n = 3850 |
P | ||
|---|---|---|---|---|---|
| n | % or mean (SD) | n | % or mean (SD) | ||
| Age (years) | 103 | 47.7 (13.2) | 3850 | 47.3 (15.3) | .78 |
| IBD type | |||||
| Crohn’s disease | 75 | 73% | 2466 | 65% | .10 |
| UC/IC | 28 | 27% | 1326 | 34% | |
| Gender (% female) | 77 | 75% | 2621 | 69% | .17 |
| Comorbidities | |||||
| Chronic lung disease (asthma, COPD) (% yes) | 22 | 21% | 628 | 16% | .17 |
| Diabetes (% yes) | 3 | 3% | 173 | 4% | .44 |
| Kidney disease (% yes) | 3 | 3% | 115 | 3% | .97 |
| History of organ transplantation (% yes) | 0 | 0% | 16 | 0% | .51 |
| Active cancer (% yes) | 1 | 1% | 56 | 1% | .68 |
| Education (% >high school) | 83 | 92% | 2852 | 95% | .26 |
| Race (%) | |||||
| Caucasian/other | 99 | 96% | 3804 | 99% | .02 |
| African American | 4 | 4% | 46 | 1% | |
| Current smoking (% yes) | 1 | 1% | 82 | 4% | .26 |
| Obesity (BMI ≥30) (% yes) | 20 | 19% | 713 | 19% | .82 |
| Medications (% yes)a | |||||
| Anti-TNF | 43 | 42% | 1438 | 38% | .42 |
| Vedolizumab | 9 | 9% | 452 | 12% | .30 |
| Ustekinumab | 14 | 14% | 421 | 11% | .47 |
| Immunomodulator (IMM)b | 20 | 19% | 823 | 22% | .59 |
| Anti-TNF + IMM | 9 | 9% | 380 | 10% | .70 |
| Corticosteroids | 8 | 8% | 376 | 10% | .48 |
| Tofacitinib | 0 | 0% | 56 | 2% | .21 |
| 5-ASA | 27 | 26% | 916 | 24% | .62 |
| Any immunosuppression (% yes) | 75 | 73% | 2707 | 70% | .58 |
| Duration of follow-up (days) | 103 | 291.2 (125.1) | 3850 | 209.5 (157.1) | <.001 |
Abbreviations: 5-ASA, 5-aminosalicylate; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.
Anti-TNF (anti-tumor necrosis factor alpha), IMM, and combination groups not mutually exclusive.
Methotrexate, azathioprine, or 6-mercaptopurine.